Lee Rosebush Comments on Compounder Suit Against FDA for Removing Tirzepatide from Shortage List

Partner Lee Rosebush is quoted in an article for Fierce Pharma titled "Compounders Sue FDA for Removing Eli Lilly's Tirzepatide from Shortage List." Published Oct. 8, 2024, the article describes how the Outsourcing Facilities Association (OFA) alleges that the FDA removed the drugs Mounjaro and Zepbound from the shortage list without due process and the action should be immediately revoked. As chairman of the OFA, Rosebush stated that the FDA's actions will result in "tremendous implications across the nation for patients and physicians."

Rosebush also commented in an article in Cardiovascular Business titled "FDA's Tirzepatide Decision Creates Uncertainty for Patients - and Leads to a Lawsuit." Published Oct. 10, 2024, the article states that the medications had been on the short list for so long that drug manufacturers, pharmacies, physicians and patients were used to obtaining a compounded version as needed.

Read the Fierce Pharma article.

Read the Cardiovascular Business article.